This may include cases of insulin resistance or prediabetes, metabolic conditions such as PCOS, or when a patient has already tried other FDA-approved weight loss drugs and not sustained results with other FDA-approved weight loss medications like Qsymia or Saxenda
General Endocrine Disorders: Complex conditions such as Type 1 and 2 Diabetes Mellitus, Secondary Adrenal Insufficiency, Multiple Endocrine Neoplasia (MEN) Syndromes, and Hypothyroidism benefit from these innovative therapies
When NAD+ levels are adequate, SIRT1 activity increases, promoting DNA repair, reducing inflammation, and enhancing stress resistance
2023;46(Suppl 1):S12839
Frequently Asked Questions In Phase 3 trials, retatrutide achieved 28.328.7% average weight loss versus tirzepatide's 22.5% a meaningful 56 percentage point difference
As a podiatrist, Im always searching for therapies that not only relieve pain but also address the underlying cause of injury